Application of PET/CT in the treatment of epidermal growth factor receptor tyrosine kinase inhibitor in patients with advanced non-small cell lung cancer
10.3760/cma.j.cn321828-20220314-00068
- VernacularTitle:PET/CT在晚期非小细胞肺癌患者EGFR－TKI治疗中的应用
- Author:
Yan CUI
1
;
Zhiming YAO
Author Information
1. 北京医院核医学科、国家老年医学中心、中国医学科学院老年医学研究院，北京 100730
- Keywords:
Carcinoma, non-small-cell lung;
Genes, erbB-1;
Protein kinase inhibitors;
Positron-emission tomography;
Tomography, X-ray computed;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2023;43(5):312-315
- CountryChina
- Language:Chinese
-
Abstract:
The morbidity and mortality of lung cancer rank first in the world. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) can significantly prolong survival of patients with advanced non-small cell lung cancer (NSCLC). 18F-FDG PET/CT can evaluate EGFR mutation status and EGFR-TKI efficacy. This article reviews the role of 18F-FDG PET/CT in predicting EFGR mutation, the efficacy and survival prognosis evaluation of EGFR-TKI therapy, as well as the development of latest EGFR-TKI PET imaging agents.
